Achaogen Inc. (NASDAQ:AKAO) shares traded up 3.1% during trading on Monday . The stock traded as high as $3.70 and last traded at $3.68, with a volume of 94,874 shares traded. The stock had previously closed at $3.57.

Several research analysts have recently commented on the company. Zacks Investment Research raised Achaogen from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Wednesday, July 6th. Wedbush upgraded shares of Achaogen from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $7.00 to $10.00 in a research report on Tuesday, June 14th. Needham & Company LLC restated a “hold” rating on shares of Achaogen in a research report on Monday, May 9th. Finally, Cowen and Company cut shares of Achaogen from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 31st. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Achaogen currently has a consensus rating of “Buy” and an average target price of $10.63.

The company’s 50 day moving average is $3.96 and its 200 day moving average is $3.69. The firm’s market capitalization is $68.11 million.

Achaogen, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.